Overview

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Polyethylene glycol 3350
Tegaserod